✦ LIBER ✦

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients

✍ Scribed by Chien-Hung Chen; Chuan-Mo Lee; Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu; Chi-Sin Changchien; Sheng-Nan Lu

Book ID: 108953844
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 412 KB
Volume: 26
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.2010.06429.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of sustained response to pegi

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

✍ Milan J. Sonneveld; Vincent Rijckborst; Charles A. B. Boucher; Bettina E. Hansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG-IFN). We investigated within a large randomized trial whether quantitative HBsAg levels predict response to PEG-IFN in patients with hepatitis B e antigen (HBeAg)-positive chronic

Durability of peginterferon alfa-2b trea

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

✍ Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Kenneth Kar-Lung Yan; Angel Mei-Ling 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 256 KB 👁 2 views

Hepatitis B virus surface antigen levels

Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

✍ Maurizia Rossana Brunetto; Francesco Moriconi; Ferruccio Bonino; George K. K. La 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 748 KB

Bristol-Myers Squibb, Gilead, and Novartis. He is also in the speakers' bureau of Schering-Plough. Dr. Lau is on the speakers' bureau of and received grants from Roche and Novartis. Dr. Piratvisuth advises and is on the speakers' bureau of Roche. He advises Novartis and Schering-Plough and is on th

Cost-effectiveness of peginterferon alfa

Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan

✍ Sean D Sullivan; David L Veenstra; Pei-Jer Chen; Ting-Tsung Chang; Wan-Long Chua 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Prediction of response to peginterferon-

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

✍ Yoshimasa Hashimoto; Hidenori Ochi; Hiromi Abe; Yasufumi Hayashida; Masataka Tsu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

## Abstract Variation at the IL‐28B locus was recently reported to be a significant predictive factor of viral response to pegylated‐interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL‐28B polymorphism rs8099917 and v

Shorter durations and lower doses of peg

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

✍ Y.-F. Liaw; J.-D. Jia; H.L.Y. Chan; K.H. Han; T. Tanwandee; W.L. Chuang; D.M. Ta 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 401 KB 👁 2 views

As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa-2a (PEG-IFNα-2a) therapy in hepatitis B e antigen (HBeAg)-positive patients, the efficacy and safety of either 24 or 48 weeks' duration and 90 μg/week or 180 μg/week doses were compared. HBeAg-p